newsfilter
← Earnings
Earnings Releases·

Edgewise Therapeutics — Third Quarter 2026 Earnings Summary

Edgewise Therapeutics reported a net income of $1.166 billion for the third quarter of 2026, driven primarily by a $1.348 billion gain from the sale of its sevasemten program to Servier. The company holds approximately $1.744 billion in cash, cash equivalents, and marketable securities as of September 30, 2026. Recent clinical progress includes the publication of EDG-7500's differentiated mechanism of action and the initiation of a Phase 3 trial for the drug in hypertrophic cardiomyopathy expected by year-end 2026. Additionally, the first patient was dosed in the Phase 2 EQUINOX-HFpEF trial evaluating EDG-15400 for heart failure with preserved ejection fraction.

Company
EDGEWISE THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology